Stocks › LRMR

Larimar Therapeutics, Inc.

LRMR·Nasdaq·United States United States·USD
$3.14
-0.08 (-2.48%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
LRMR
Larimar Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
LRMRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of LRMR by members of U.S. Congress · 0 on record

No congressional trades in LRMR on record.

Whale Activity

Position changes in LRMR reported for 2026-09-30 by 176 institutional filers
Increased: 50New: 13Held: 28Decreased: 55Closed: 29No prior filing: 1
  • Increased50
  • New13
  • Held28
  • Decreased55
  • Closed29
  • No prior filing1
FilerSharesValueChange
DEERFIELD MANAGEMENT COMPANY, L.P.35.6M$113.8Mheld
Blue Owl Capital Holdings LP9.9M$31.7Mincreased
RTW INVESTMENTS, LP5.8M$18.6Mincreased
BlackRock, Inc.5.8M$18.4Mincreased
Defilade Capital Management, L.P.4.9M$15.8Mincreased
DRIEHAUS CAPITAL MANAGEMENT LLC3.1M$10.0Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC3.0M$9.5Mheld
GOLDMAN SACHS GROUP INC3.0M$9.5Mincreased
AQR CAPITAL MANAGEMENT LLC2.2M$7.2Mdecreased
MARSHALL WACE, LLP2.2M$7.0Mincreased
DAFNA Capital Management LLC1.9M$6.0Mdecreased
BANK OF AMERICA CORP /DE/1.9M$6.0Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by LRMR insiders, by quarter · Form 4
-10.0M-5.0M05.0M10.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 5.1M2026 Q12026 Q2: 02026 Q22026 Q3: 50.0K2026 Q32026 Q4: 147.4K2026 Q4

Recent Insider Transactions

58 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Clayton RussellChief Medical Officer Purchase +3,322 $3.01 $10K Nov 16, 2026 Form 4 ↗
SHERMAN JEFFREY WDirector · Director Purchase +3,289 $3.06 $10K Nov 16, 2026 Form 4 ↗
Hamilton Thomas EdwardDirector · Director Purchase +70.0K $2.67 $187K Nov 12, 2026 Form 4 ↗
BEN-MAIMON CAROLEPresident and CEO · Director Purchase +18.1K $2.77 $50K Nov 11, 2026 Form 4 ↗
THOMAS FRANK EDirector · Director Purchase +8,000 $2.73 $22K Nov 11, 2026 Form 4 ↗
Truitt JosephDirector · Director Purchase +3,500 $2.80 $10K Nov 11, 2026 Form 4 ↗
Harlow John B. Jr.President and COO Purchase +17.8K $2.80 $50K Nov 11, 2026 Form 4 ↗
Celano MichaelChief Financial Officer Purchase +18.5K $2.71 $50K Nov 11, 2026 Form 4 ↗
Shankar GopiChief Development Officer Purchase +5,000 $2.71 $14K Nov 11, 2026 Form 4 ↗
Hamilton Thomas EdwardDirector Purchase +50.0K $3.34 $167K Jul 6, 2026 Form 4 ↗
Deerfield Mgmt HIF, L.P.Director · 10% owner Purchase +2.0M $5.00 $10.0M Feb 27, 2026 Form 4 ↗
Deerfield Mgmt HIF, L.P.Director · 10% owner Purchase +832.0K $5.00 $4.2M Feb 27, 2026 Form 4 ↗
Deerfield Mgmt HIF, L.P.Director · 10% owner Purchase +1.1M $5.00 $5.4M Feb 27, 2026 Form 4 ↗
Deerfield Mgmt HIF, L.P.Director · 10% owner Purchase +1.1M $5.00 $5.4M Feb 27, 2026 Form 4 ↗
Hamilton Thomas EdwardDirector Purchase +100.0K $5.00 $500K Feb 27, 2026 Form 4 ↗
THOMAS FRANK EDirector Purchase +5,000 $5.00 $25K Feb 27, 2026 Form 4 ↗
SHERMAN JEFFREY WDirector Purchase +5,000 $5.00 $25K Feb 27, 2026 Form 4 ↗
Shankar GopiChief Development Officer Grant / award +25.6K $0.00 $0 Jan 26, 2026 Form 4 ↗
Clayton RussellChief Medical Officer Grant / award +25.6K $0.00 $0 Jan 26, 2026 Form 4 ↗
BEN-MAIMON CAROLEPresident and CEO · Director Grant / award +100.1K $0.00 $0 Jan 26, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding LRMR · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.2M$6.7M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.7M$5.3M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
726.5K$2.8M0.01%Jul 31, 2026
VANGUARD EXPLORER FUND659.1K$2.5M0.01%Jul 31, 2026
Fidelity Enhanced Small Cap Core ETF
Fidelity Covington Trust
814.6K$2.5M0.04%Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account
College Retirement Equities Fund
757.6K$2.3M0.00%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
699.5K$2.1M0.00%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
625.2K$1.9M0.01%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
382.5K$1.5M0.01%Aug 31, 2026
Dimensional U.S. Small Cap ETF
Dimensional ETF Trust
340.8K$1.3M0.01%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list LRMR's shares (CUSIP 517125100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Roderick WongSCHEDULE 13G · passive (13G) · 5.8M shares5.6%
    Nov 16, 2026 · ↗
  • RTW Investments, LPSCHEDULE 13G · passive (13G) · 5.8M shares5.6%
    Nov 16, 2026 · ↗
  • Blue Owl Capital Holdings LPSCHEDULE 13G/A · passive (13G) · 10.7M shares10.0%
    May 14, 2026 · ↗
  • Israel A. EnglanderSCHEDULE 13G/A · passive (13G) · 3.6M shares3.5%
    Apr 30, 2026 · ↗
  • Millennium Group Management LLCSCHEDULE 13G/A · passive (13G) · 3.6M shares3.5%
    Apr 30, 2026 · ↗
  • Millennium Management LLCSCHEDULE 13G/A · passive (13G) · 3.6M shares3.5%
    Apr 30, 2026 · ↗
  • GOLDMAN SACHS & CO. LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares4.1%
    May 13, 2025 · ↗
  • THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G/A · passive (13G) · 2.6M shares4.1%
    May 13, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Larimar Therapeutics, Inc. as client

No lobbying filings found naming Larimar Therapeutics, Inc. as the client.

Government Contracts

Federal awards to Larimar Therapeutics, Inc. · USAspending

No federal contract awards found for Larimar Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Larimar Therapeutics, Inc.

No USPTO patent applications found for Larimar Therapeutics, Inc..

Annual Financials

From LRMR's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$172.5M-$90.9M-$41.8M-$36.5M-$50.5M
Net income-$165.7M-$80.6M-$36.9M-$35.4M-$50.6M
Diluted EPSn/a-$1.32-$0.84-$1.37-$2.95
Operating cash flow-$113.2M-$70.8M-$33.5M-$27.6M-$42.1M
Cash and equivalents$85.4M$33.2M$26.7M$26.8M$70.1M
Total assets$145.8M$200.2M$95.9M$126.4M$78.7M
Total liabilities$67.8M$28.4M$14.2M$15.5M$14.3M
Shareholders' equity$78.1M$171.8M$81.7M$110.9M$64.4M

As Larimar Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-12Reverse splitMay 29, 2020

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 16, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 29, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 19, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsMay 14, 2026
    EDGAR ↗

About Larimar Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBALA CYNWYD, PA
IncorporatedDE
Former namesZAFGEN, INC., ZAFGEN INC